- Board-certified medical doctor for laboratory medicine (clinical pathologist)
- Adjunct Professor of Applied Immunology at the University of Heidelberg
- Founder, managing director and owner of ImmBioMed Business Consultants GmbH & Co. KG
- Owner of LOXO GmbH
Michael Kramer was born in Jugenheim in 1958 and studied medicine at the University of Heidelberg from 1977. In 1985 he received his licence to practise medicine and in the same year he received his doctorate in medicine from the University of Heidelberg. In 1992 he was awarded the Venia Legendi for “Applied Immunology” at the University of Heidelberg. In 1999 he was admitted as a specialist in laboratory medicine and the additional certification as “Medical Quality Management”. In addition, he acquired the certification of “Transfusion Medicine” in 2000. In December 1999 he was appointed Professor (adjunct) of Applied Immunology at the University of Heidelberg. Michael Kramer is married and has two children.
Professional background and business development
1979 – 1985 Student assistant at the German Cancer Research Centre in Heidelberg
1985 – 1987 military service at the Central Institute of the Medical Service of the German Armed Forces in Koblenz
1987 – 1998 Various clinics and institutes of the Heidelberg University Hospital; from 1992 -1998 Senior Assistant at the Institute of Immunology at the University of Heidelberg and Head of the Laboratory of Immunopathology
1999 – 2003 Managing Director of LYNX Therapeutics GmbH in Heidelberg; a subsidiary of Lynx Therapeutics Inc, Hayward, CA, USA
From 2003 foundation and development of ImmBioMed Business Consultants GmbH & Co. KG
From 2007 foundation and development of a laboratory practice in Heidelberg
08/2017 Acquisition of LOXO GmbH (www.loxo.de)
03/2018 Acquisition of the business unit “Specialty Coagulation” of Sekisu Diagnostics GmbH (Press Release)
1985 Julius Redel Prize of the Medical Faculty of Heidelberg University
1989 Paul-Gersson-Unna Prize of the German Dermatological Society
1998 Robert Pfleger Prize for Biomedical Research
Kramer, M.D., L. Binninger, V. Schirrmacher, H. Moll, M. Prester, G. Nerz, and M.M. Simon. 1986
Characterization and isolation of a trypsin-like serine protease from a long-term culture cytolytic T cell line and its expression by functionally distinct T cells.
Simon, M.M., H. Hoschützky, U. Fruth, H.-G. Simon, and M.D. Kramer. 1986
Purification and characterization of a T cell specific serine proteinase (TSP-1) from cloned cytolytic T lymphocytes.
EMBO J. 5:3267-3274.
Kramer, M.D. and Simon M.M. 1987
Are proteinases functional molecules of T lymphocytes?
Immunology Today 8:140-142.
Kramer, M.D., U.E. Schaible, R. Wallich, S.E. Moter, D. Petzoldt, M.M. Simon. 1990
Characterization of Borrelia burgdorferi associated antigens by monoclonal antibodies.
Schaible, U.E., M.D. Kramer, K. Eichmann, M. Modolell, C. Museteanu, and M.M. Simon. 1990
Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice.
Proc. Natl. Acad. Sci. USA 87:3768-3772.
Simon M.M., U.E. Schaible, R. Wallich, and M.D. Kramer. 1991.
A mouse model for Borrelia burgdorferi infection: approach to a possible vaccine against
Immunology Today 12:11-16.
Kramer, M.D. and J. Reinartz. 1993.
The autoimmune blistering skin disease bullous pemphigoid: The presence of plasmin/
a2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.
Clin. Invest. 92:978-983.
Reinartz J., R. Batrla, P. Boukamp, N. Fusenig, and M.D. Kramer. 1993.
Binding and activation of plasminogen at the surface of human keratinocytes.
Exp. Cell Res. 208:197-208.
Fuchs H., R. Wallich, M.M. Simon, and M.D. Kramer. 1994.
The outer surface protein A of the spirochete Borrelia burgdorferi is a plasmino(gen) receptor.
Proc. Natl. Acad. Sci: USA 91: 12594-12598.
Moter, S.E., H. Hofmann, R. Wallich, M.M. Simon, and M.D. Kramer. 1994.
Detection of Borrelia burgdorferi sensu lato in lesional skin of erythema migrans and acrodermatitis chronica atrophicans by OspA-specific polymerase chain reaction.
Clin. Microbiol. 32:2980-2988.
Foekens J.A., F. Buessecker, H.A. Peters, U. Krainick, W.L.J. van Putten, and M.D. Kramer. 1995.
Plasminogen activator inhibitor-2 (PAI-2): prognostic relevance in 1012 patients with primary breast cancer.
Cancer Res. 55:1423-1427.
Fuchs H., M.M. Simon, R. Wallich, M. Bechtel, and M.D. Kramer. 1996.
Borrelia burgdorferi induces the secretion of pro-urokinase-type plasminogen activator by human monocytes.
Infect. Immun. 64:4307-4312.
Bechtel M. J., J. Rox, S. Inndorf, J. Reinartz, B. Schaefer, and M.D. Kramer. 1996.
Upregulation of cell surface-associated plasminogen activation in cultured keratinocytes by Interleukin-1beta and Tumor-Necrosis-Factor-alpha.
Exp. Cell. Res. 223:395-404.
Schaefer B., C. Jaeger, E. Drepper, and M.D. Kramer. 1996.
Plasminogen activation in bullous pemphigoid. Immunohistology revels uPA, uPA-R, and PAI-2 in lesional epidermis.
Schaefer B.M., J. Reinartz, M.J. Bechtel, S. Inndorf, E. Lang, M.D. Kramer. 1996.
Dispase-mediated basal detachment of cultured keratinocytes induces urokinase-type plasminogen activator (uPA9 and its receptor (uPA-R, CD87).
Exp. Cell. Res. 228:246-253.
Schaefer M.D., C. Jaeger, and M.D. Kramer. 1996.
The plasminogen activator system in pemphigus vulgaris.
Br. J. Dermatol. 135:726-732.
Schott D., C.-E. Dempfle, P. Beck, A. Liermann, A. Mohr-Pennert, M. Goldner, P. Mehlem, H. Azuma, V. Schuster, A.-M. Mingers, H.P. Schwarz, and M.D. Kramer.1998
Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency.
New Engl. J. Med. 339:1679-1686.
ImmBioMed Business Consultants GmbH & Co. KG
Telefon: +49 171 956 3808
Telefax: +49 6157 86443